Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biosergen AB
  6. News
  7. Summary
    BIOSGN   SE0016013460

BIOSERGEN AB

(BIOSGN)
SummaryQuotesChartsNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biosergen : Wins Australian Approval To Start Human Trials For Antifungal Drug

08/24/2021 | 06:08am EST


ę MT Newswires 2021
All news about BIOSERGEN AB
02:28aBiosergen publishes interim report for the third quarter 2021
AQ
08/31BIOSERGEN : publishes interim report for the second quarter 2021
AQ
08/31Biosergen AB Reports Consolidated Earning Results for the Second Quarter of 2021
CI
08/24BIOSERGEN : Wins Australian Approval To Start Human Trials For Antifungal Drug
MT
08/24BIOSERGEN : application to start human clinical trials with BSG005 is approved
AQ
08/24Biosergen’s Application to Start Human Clinical Trials with BSG005
CI
08/19BIOSERGEN : Tine Kold Olesen will join Biosergen AB as Chief Operating Officer
AQ
08/19Tine Kold Olesen to Join Biosergen AB as Chief Operating Officer, Effective October 1, ..
CI
06/27BIOSERGEN : groundbreaking antifugal drug BSG005 is granted Orphan Drug status in the Unit..
AQ
More news
Chart BIOSERGEN AB
Duration : Period :
Biosergen AB Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
Peder M°ller Andersen Chief Executive Officer
Niels Laursen Chief Financial Officer
Torsten RŘdiger Goesch Chairman
Richard Forster Chief Technology Officer
Lena Birgitta Degling Wikingsson Independent Director